You are here: Home » PTI Stories » National » News
Business Standard

Abbott India shares jump over 5% post Q2 earnings

Press Trust of India  |  New Delhi 

of pharma firm today rose by over 5 per cent after the company reported a 22.66 per cent rise in standalone net profit for the quarter ended September.

The stock jumped 4.88 per cent to end at Rs 4,925 on BSE. Intra-day, it gained 5.41 per cent to Rs 4,950.



At NSE, of the company surged 5.25 per cent to close at Rs 4,939.55.

today reported a 22.66 per cent rise in standalone net profit at Rs 75.02 crore for the quarter ended September, mainly on account of robust sales.

The company had posted a net profit of Rs 61.16 crore in the year-ago period, said in a filing.

Standalone total from operations also rose to Rs 729.43 crore during the quarter under review from Rs 648.98 crore a year ago.

offers medicines in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders and primary care.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Abbott India shares jump over 5% post Q2 earnings

Shares of pharma firm Abbott India today rose by over 5 per cent after the company reported a 22.66 per cent rise in standalone net profit for the quarter ended September. The stock jumped 4.88 per cent to end at Rs 4,925 on BSE. Intra-day, it gained 5.41 per cent to Rs 4,950. At NSE, shares of the company surged 5.25 per cent to close at Rs 4,939.55. Abbott India today reported a 22.66 per cent rise in standalone net profit at Rs 75.02 crore for the quarter ended September, mainly on account of robust sales. The company had posted a net profit of Rs 61.16 crore in the year-ago period, Abbott India said in a BSE filing. Standalone total income from operations also rose to Rs 729.43 crore during the quarter under review from Rs 648.98 crore a year ago. Abbott India offers medicines in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders and primary care. of pharma firm today rose by over 5 per cent after the company reported a 22.66 per cent rise in standalone net profit for the quarter ended September.

The stock jumped 4.88 per cent to end at Rs 4,925 on BSE. Intra-day, it gained 5.41 per cent to Rs 4,950.

At NSE, of the company surged 5.25 per cent to close at Rs 4,939.55.

today reported a 22.66 per cent rise in standalone net profit at Rs 75.02 crore for the quarter ended September, mainly on account of robust sales.

The company had posted a net profit of Rs 61.16 crore in the year-ago period, said in a filing.

Standalone total from operations also rose to Rs 729.43 crore during the quarter under review from Rs 648.98 crore a year ago.

offers medicines in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders and primary care.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Abbott India shares jump over 5% post Q2 earnings

of pharma firm today rose by over 5 per cent after the company reported a 22.66 per cent rise in standalone net profit for the quarter ended September.

The stock jumped 4.88 per cent to end at Rs 4,925 on BSE. Intra-day, it gained 5.41 per cent to Rs 4,950.

At NSE, of the company surged 5.25 per cent to close at Rs 4,939.55.

today reported a 22.66 per cent rise in standalone net profit at Rs 75.02 crore for the quarter ended September, mainly on account of robust sales.

The company had posted a net profit of Rs 61.16 crore in the year-ago period, said in a filing.

Standalone total from operations also rose to Rs 729.43 crore during the quarter under review from Rs 648.98 crore a year ago.

offers medicines in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders and primary care.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22